Surgery Websites
Thoracic Oncology Program »  Meet the Team »  Medical Oncologists »  Collin Blakely, M.D., Ph.D.
Collin Blakely, M.D., Ph.D.

Collin Blakely, M.D., Ph.D.

Assistant Clinical Professor
Division of Hematology/Oncology
Department of Medicine

Contact Information

(415) 885-3882  Patients & Clinic 
(415) 353-9525  Fax
Open Popup

University of Washington, B.S. 1997
University of Pennsylvania, M.D., Ph.D. 2007

  • Hospital of the University of Pennsylvania, Internship in Internal Medicine, 2007-2008

  • Hospital of the University of Pennsylvania, Residency in Internal Medicine, 2008-2009
  • UCSF, Fellowship in Medical Oncology, 2009-2011
  • Postdoctoral Fellow - UCSF, Lisa Coussens Laboratory, 2010-2012

  • Postdoctoral Fellow - UCSF, Trever Bivona Laboratory, 2012-2014
  • Non-small cell lung cancer
  • Small cell lung cancer
  • ALK-rearranged lung cancer
  • EGFR-mutant lung cancer
  • Mechanisms of resistance to targeted therapies
  • ROS1-rearranged lung cancer

Collin is a medical oncologist specializing in the treatment of lung cancer. He received his Bachelor of Science degree in Molecular and Cellular Biology from the University of Washington and attended the Perelman School of Medicine at the University of Pennsylvania in the Medical Scientist Training Program. He completed his Internal Medicine residency at the Hospital of the University of Pennsylvania and trained as a clinical fellow in Medical Oncology at UCSF. His research focuses on understanding the cellular and molecular mechanisms underlying lung cancer resistance to EGFR-targeted therapies. His goal is to translate laboratory-based findings into new treatments for lung cancer patients.

  Award  
  Confired By    
  Date    
  • Damon Runyon Clinical Investigator Award
  • Damon Runyon Cancer Research Foundation
  • 2018 - 2021
  • V Scholar Award
  • V Foundation
  • 2018 - 2020
  • Clinical Scientist Award
  • Doris Duke Charitable Foundation
  • 2018 - 2012
  • AACR BioOncology Fellowship
  • AACR
  • 2014 - 2016
  • Legacy Award
  • Uniting Against Lung Cancer
  • 2014 - 2016
  • Research Grant
  • Bonnie J. Addario Lung Cancer Foundation
  • 2013
  • The primary focus of my research is to translate laboratory-based findings into novel investigator sponsored trials that aim to assess the safety and efficacy of rationally designed targeted therapies for lung cancer patients.

    My goals are to: 1) define how TKI resistance pathways evolve at the tumor genome, transcriptome and molecular signaling levels within lung cancers and to translate these findings into novel prognostic and predictive biomarkers that may predict TKI resistance before it occurs; 2) develop investigator sponsored clinical trials to test rational companion therapies that can prevent, delay, or overcome TKI resistance, 3) develop investigator sponsored clinical trials to target recently identified oncogenic pathways, outside of EGFR and ALK, that drive NSCLC; and 4) establish a cohort of patient-derived xenograft (PDX) mice to foster research that aims to further understand the molecular mechanisms of response and resistance to TKI therapies in lung cancer

    Data provided by UCSF Profiles, powered by CTSI
    MOST RECENT PUBLICATIONS FROM A TOTAL OF 36
    Data provided by UCSF Profiles, powered by CTSI
    1. Woodard GA, Kratz JR, Haro G, Gubens MA, Blakely CM, Jones KD, Mann MJ, Jablons DM. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy. Clin Lung Cancer. 2021 Aug 20. View in PubMed
    2. Tsuboi M, Weder W, Escriu C, Blakely C, He J, Dacic S, Yatabe Y, Zeng L, Walding A, Chaft JE. Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA. Future Oncol. 2021 Jul 19. View in PubMed
    3. Wu SY, Lazar AA, Gubens MA, Blakely CM, Gottschalk AR, Jablons DM, Jahan TM, Wang VEH, Dunbar TL, Wong ML, Chan JW, Guthrie W, Belkora J, Yom SS. Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial. JAMA Netw Open. 2020 09 01; 3(9):e209750. View in PubMed
    4. Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, Jones K, Sit R, Kolli PK, Seeley E, Gesthalter Y, Le DD, Yamauchi KA, Naeger DM, Bandyopadhyay S, Shah K, Cech L, Thomas NJ, Gupta A, Gonzalez M, Do H, Tan L, Bacaltos B, Gomez-Sjoberg R, Gubens M, Jahan T, Kratz JR, Jablons D, Neff N, Doebele RC, Weissman J, Blakely CM, Darmanis S, Bivona TG. Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. Cell. 2020 09 03; 182(5):1232-1251.e22. View in PubMed
    5. Blakely CM, McCoach CE. Role of MPR as an Early Signal for Efficacy in Neoadjuvant Studies. Clin Cancer Res. 2020 07 15; 26(14):3499-3500. View in PubMed
    6. View All Publications

     

    Site Directory
      X